S0820, Adenoma and Second Primary Prevention Trial (PACES)S0820, Adenoma and Second Primary Prevention Trial (PACES)

Primary Objective

To assess whether eflornithine (+/- sulindac), sulindac (+/- eflornithine) or the combination are effective in reducing the three-year event rate (high-risk adenomas and second primary colorectal cancers) in patients with previously treated Stage 0-III colon cancer.

Secondary Objectives

To assess whether eflornithine, sulindac or the combination has efficacy against colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, any adenomas ≥ 0.3 cm, total advanced colorectal events, or total colorectal events.
To assess quantitative and qualitative toxicities of patients when treated with eflornithine, sulindac, or the combination compared to placebo.
To evaluate a minimal set of tagging single nucleotide polymorphisms across multiple genes relevant to eflornithine and sulindac, in order to characterize associations with decreased adenoma/second primary colorectal cancer (CRC) risk and adverse events.
To examine the interaction of intervention arm and baseline statin use with respect to the 3-year event rate.
To examine the interaction of the intervention arm and patient-reported meat consumption with respect to the 3-year event rate.
(Arizona Cancer Center, M.D. Anderson Cancer Center, UC Irvine Medical Center and Wichita CCOP ONLY) To perform population pharmacokinetic (PK) analysis of eflornithine and sulindac in patients with previously treated Stage 0-III colon cancer.

Age18 years and older
GenderBoth

Contact Us

For more information about this study, including how to volunteer, contact:

Christina Wiess

Phone Number: 1-203-737-3472
christina.wiess@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

CREATE A VOLUNTEER PROFILE

Trial Purpose and Description

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.

Eligibility Criteria

Inclusion Criteria:

History of Stage 0-III colon or rectal cancer with primary resection 1 year previously
Post-operative colonoscopy and CT scans of chest, abdomen & pelvis showing no evidence of disease
Must not have cardiovascular risk factors including unstable angina, history of myocardial infarction, or cerebrovascular accident, coronary artery bypass surgery, or NY Heart Assoc Class III or IV heart failure.
Patients must not have known uncontrolled hyperlipidemia (defined as LDL-C >/= 190 mg/dL or triglycerides >/= 500 mg/dL within the past 3 years or uncontrolled high blood pressure (systolic blood pressure > 150 mm Hg) within 28 days prior to registration
At least 30 days from completion of adjuvant chemo and RT.
Presence of gastroesophageal reflux disease acceptable if controlled with medications
Not receiving or planning to receive concomitant corticosteroids,nonsteroidal anti-inflammatory drugs(NSAIDs), nor anticoagulants. Maximum aspirin dose
- 100 mg per day or ≤ two 325 mg tablets per week.
Able to swallow oral medications
Laboratory: WBC ≥ 4.0 x 103/mcL, platelets ≥ 100,000/mcL and hemoglobin > 11.0 g/dL. Serum bilirubin ≤ 2.0 mg/dL and AST (SGOT) or ALT(SGPT) ≤ 2 x IULN. Serum creatinine ≤ 1.5 x IULN
Zubrod PS 0-1, 18 years of age or older
Will not participate in any other clinical trial for the treatment or prevention of cancer unless off protocol treatment, on follow-up phase only
Offered opportunity to participate in blood specimen banking

Exclusion Criteria:

History of colon resection > 40 cm
Mid-low rectal cancer
Recurrent or metastatic disease
High cardiovascular risk; Uncontrolled hypertension
Planned radiation therapy or additional chemotherapy
Documented history of gastric/duodenal ulcer within last 12 months and/or current treatment or active symptoms of gastric/duodenal ulcer
Known history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or inflammatory bowel disease
≥ 30 dB uncorrectable hearing loss for age of any of the five tested frequencies on prestudy audiogram
Known hypersensitivity to sulindac or excipient byproducts. Previous asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs
Significant medical or psychiatric condition that would preclude study completion (8 years)
No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for > 5 years
Pregnant or nursing women. Women/men of reproductive potential must agree to use effective contraception